Immune-Onc Therapeutics: Funding, Investors & Team (Sep 2026)
A recently founded biopharmaceutical business called Immune-Onc Therapeutics focuses on creating novel therapeutic antibodies for the treatment of cancer. The company advances novel immuno-oncology drugs and offers cancer patients new therapy alternatives by utilising the most recent scientific understandings and medication development capabilities.
Immune-Onc Therapeutics has raised $25.0M across 1 funding round on record, the most recent a Series B of $25.0M announced in Jan 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Immune-Onc Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2023.
Immune-Onc Therapeutics Funding Rounds
Immune-Onc Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Immune-Onc Therapeutics Funding Compared to Other Biotechnology Startups
Immune-Onc Therapeutics' latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Immune-Onc Therapeutics in Biotechnology and Palo Alto
Companies Similar to Immune-Onc Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Immune-Onc Therapeutics Funding FAQs
What does Immune-Onc Therapeutics do?
A recently founded biopharmaceutical business called Immune-Onc Therapeutics focuses on creating novel therapeutic antibodies for the treatment of cancer. The company advances novel immuno-oncology drugs and offers cancer patients new therapy alternatives by utilising the most recent scientific understandings and medication development capabilities.
How much funding has Immune-Onc Therapeutics raised?
Immune-Onc Therapeutics has raised $25.0M across 1 round on record. The most recent is a Series B of $25.0M announced in Jan 2023.
When did Immune-Onc Therapeutics last raise funding?
Immune-Onc Therapeutics' most recent funding round on record is a Series B of $25.0M, announced in Jan 2023.
Who is the CEO of Immune-Onc Therapeutics?
Charlene Liao is listed as CEO at Immune-Onc Therapeutics.
Where is Immune-Onc Therapeutics headquartered?
Immune-Onc Therapeutics is based in Palo Alto, California, United States.
How many employees does Immune-Onc Therapeutics have?
Immune-Onc Therapeutics is in the 11-50 employee band.
How does Immune-Onc Therapeutics' funding compare to other Biotechnology startups?
Immune-Onc Therapeutics' latest round of $25.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Immune-Onc Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Immune-Onc Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.